Modifying soft tissue sarcoma chemotherapy regimens. Old drugs and new horizons

Abstract

We report results of single institution trial of 78 STS pts treated with front line high dose doxorubicin with ifosfamide in comparison with 50 pts treated retrospectively with standard MAID regimen. We achieved 44% increase in PFS (from 5 to 7.2 month) and OS (from 10 to 19.2 month) in high dose subgroup (p=0.00001). New regimen showed high activity and durable toxicity profile and can be used routinely only in specialized sarcoma centers across the country.